DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Jackisch C, Hegg R, Stroyakovskiy D, Ahn JS, Melichar B, Chen SC. et al.
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
Eur J Cancer 2016;
62: 62-75
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.